Company Analysis
Sign in

Bristol-Myers Squibb Co. (BMY)

NYSE: BMY · Pharmaceutical Preparations · Princeton, NJ · filing with the SEC since 1994
Full chart Alerts Compare
Grade6.4
◀ Past 7.7● Present 6.6▶ Future 4.9
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

7,855 patents granted to the 68 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Bristol-Myers Squibb Co.’s names, not what it holds today.

Patents granted
7,855
7,728 utility, 72 design, 36 reissue, 19 statutory invention registration, 1976 to Dec 31, 2025
Granted in 2025
163
Against 151 in 2024 and 133 in 2023
Applications published
5,352
222 of them in 2025
Names they are printed under
68
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals344
Organic fine chemistry271
Biotechnology111
Analysis of biological materials34
Medical technology27
Measurement8
Computer technology6
Chemical engineering4
Basic materials chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name68 counted
BRISTOL-MYERS SQUIBB COMPANY its own name
US, as the owner printed on each patent
3,792 granted
1,400 published
E.R. SQUIBB & SONS. INC. a subsidiary
US, as the owner printed on each patent
1,574 granted
2 published
BRISTOL-MYERS SQUIBB COMPANY its own name
named as the applicant on its applications, in US
0 granted
1,338 published
ZYMOGENETICS INC. a subsidiary
US, as the owner printed on each patent
740 granted
598 published
Celgene Corporation a subsidiary
US, as the owner printed on each patent
549 granted
250 published
Celgene Corporation a subsidiary
named as the applicant on its applications, in US
0 granted
384 published
Bristol-Myers Squibb Pharma Company a subsidiary
US, as the owner printed on each patent
243 granted
50 published
Juno Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent. 34 more under the same name are not counted (printed in DE)
57 granted
167 published
Signal Pharmaceuticals, LLC a subsidiary
US, as the owner printed on each patent
161 granted
61 published
Abraxis BioScience, LLC a subsidiary
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in CA)
82 granted
91 published
Celgene Quanticel Research, Inc. a subsidiary
US, as the owner printed on each patent
104 granted
63 published
Kosan Biosciences Incorporated a subsidiary
US, as the owner printed on each patent
109 granted
38 published
Abraxis BioScience, LLC a subsidiary
named as the applicant on its applications, in US
0 granted
80 published
Mirati Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
79 published
AMIRA PHARMACEUTICALS, INC. a subsidiary
US, as the owner printed on each patent
22 granted
55 published
ZymoGenetics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
73 published
E.R. SQUIBB & SONS, L.L.C. a subsidiary
US, as the owner printed on each patent
53 granted
18 published
Signal Pharmaceuticals, LLC a subsidiary
named as the applicant on its applications, in US
0 granted
69 published
Receptos LLC a subsidiary
US, as the owner printed on each patent
32 granted
32 published
MIRATI THERAPEUTICS, INC. a subsidiary
US, as the owner printed on each patent
39 granted
17 published
Cardioxyl Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
37 granted
8 published
2seventy bio, Inc. a subsidiary
US, as the owner printed on each patent. 7 more under the same name are not counted (printed in GB)
21 granted
22 published
CELGENE QUANTICEL RESEARCH, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
39 published
Genpharm International a subsidiary
US, as the owner printed on each patent
30 granted
8 published
MyoKardia, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
38 published
E.R. Squibb & Sons, L.L.C. a subsidiary
named as the applicant on its applications, in US
0 granted
36 published
X-BODY, INC. a subsidiary
US, as the owner printed on each patent
30 granted
4 published
Cardioxyl Pharmaceuticals, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
31 published
Delinia, Inc. a subsidiary
US, as the owner printed on each patent
9 granted
17 published
TURNING POINT THERAPEUTICS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
26 published
INHIBITEX, INC. a subsidiary
US, as the owner printed on each patent
19 granted
5 published
Pharmion LLC a subsidiary
US, as the owner printed on each patent
15 granted
9 published
Celgene International II Sàrl a subsidiary
named as the applicant on its applications, in CH
0 granted
22 published
Innate Tumor Immunity, Inc. a subsidiary
US, as the owner printed on each patent
21 granted
1 published
Innate Tumor Immunity, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
22 published
AbVitro LLC a subsidiary
US, as the owner printed on each patent
15 granted
6 published
Receptos, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
21 published
Turning Point Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
18 granted
2 published
VentiRx Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
10 granted
10 published
2seventy bio, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
19 published
iPierian, Inc. a subsidiary
US, as the owner printed on each patent
10 granted
9 published
X-BODY, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
18 published
Celgene International II Sàrl a subsidiary
CH, as the owner printed on each patent. 1 more under the same name are not counted (printed in US)
17 granted
0 published
AbVitro LLC a subsidiary
named as the applicant on its applications, in US
0 granted
15 published
Karuna Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
14 published
MYOKARDIA, INC. a subsidiary
US, as the owner printed on each patent
12 granted
2 published
Impact Biomedicines, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
12 published
Flexus Biosciences, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
10 published
Deuteria Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
4 granted
5 published
Juno Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US. 22 more under the same name are not counted (printed in DE)
0 granted
9 published
Flexus Biosciences, Inc. a subsidiary
US, as the owner printed on each patent
8 granted
0 published
RayzeBio, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
8 published
iPierian, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
8 published
Karuna Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
7 granted
0 published
Padlock Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
7 published
CORMORANT PHARMACEUTICALS AB a subsidiary
named as the applicant on its applications, in SE
0 granted
6 published
Padlock Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
6 granted
0 published
Gloucester Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
0 granted
5 published
RayzeBio, Inc. a subsidiary
US, as the owner printed on each patent
4 granted
1 published
CORMORANT PHARMACEUTICALS AB a subsidiary
SE, as the owner printed on each patent
3 granted
1 published
VentiRx Pharmaceuticals, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
4 published
Impact Biomedicines, Inc. a subsidiary
US, as the owner printed on each patent
2 granted
0 published
KOSAN BIOSCIENCES, INC., A Delaware corporation a subsidiary
US, as the owner printed on each patent
0 granted
2 published
AMIRA PHARMACEUTICALS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
1 published
Adnexus, A Bristol-Myers Squibb R&D Company a subsidiary
US, as the owner printed on each patent
0 granted
1 published
Bristol-Myers Squibb TGF BETA Inc. a subsidiary
named as the applicant on its applications, in CA
0 granted
1 published
Delinia, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
1 published
PHARMION LLC a subsidiary
named as the applicant on its applications, in US
0 granted
1 published
Names not counted (4)
Celgene CAR LLC
Most of its patents print BM; this name counts in US. 44 granted and 0 published under it are not counted.
Celgene CAR LLC
Most of its patents print BM; this name counts in US. 0 granted and 34 published under it are not counted.
BRISTOL MYERS SQUIBB CO
Most of its patents print IT; this name counts in US. 4 granted and 0 published under it are not counted.
BRISTOL MYERS SQUIBB CO
No country is printed for it. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,510,533Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrileAnalysis of biological materialsCelgene Corporation
Dec 30, 202512,509,461Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrationsOrganic fine chemistryBRISTOL-MYERS SQUIBB COMPANY
Dec 9, 202512,492,238Glypican-3-binding fibronectin based scaffold moleculesPharmaceuticalsBRISTOL-MYERS SQUIBB COMPANY
Dec 9, 202512,492,217Reagents and their use for modular enantiodivergent synthesis of C-P bondsOrganic fine chemistryBRISTOL-MYERS SQUIBB COMPANY
Dec 9, 202512,492,202Macrocyclic PAD4 inhibitors useful as immunosuppressantOrganic fine chemistryBRISTOL-MYERS SQUIBB COMPANY
Dec 9, 202512,492,1881H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosisOrganic fine chemistryBRISTOL-MYERS SQUIBB COMPANY
Dec 9, 202512,492,186Bicyclic heterocyclic compounds useful as IRAK4 inhibitorsOrganic fine chemistryBRISTOL-MYERS SQUIBB COMPANY
Dec 9, 202512,492,172Substituted quinazolinyl compounds useful as T cell activatorsPharmaceuticalsBRISTOL-MYERS SQUIBB COMPANY
Dec 2, 202512,486,525Methods for increasing productivity of therapeutic proteinsBiotechnologyBRISTOL-MYERS SQUIBB COMPANY
Dec 2, 202512,486,281Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewithOrganic fine chemistryCelgene Corporation
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388606AZAQUINAZOLINE PAN-KRAS INHIBITORSOrganic fine chemistryMirati Therapeutics, Inc.
Dec 25, 20252025/0387482METHODS FOR ISOLATING, CULTURING, AND GENETICALLY ENGINEERING IMMUNE CELL POPULATIONS FOR ADOPTIVE THERAPYMedical technologyJuno Therapeutics, Inc.
Dec 18, 20252025/0382640LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDSPharmaceuticalsJuno Therapeutics, Inc.
Dec 18, 20252025/0382368METHODS OF TREATING A NON-SMALL CELL LUNG CANCER USING AN ANTI-PD-1 ANTIBODYPharmaceuticalsBRISTOL-MYERS SQUIBB COMPANY
Dec 18, 20252025/0382290SALTS OF SOS1 INHIBITORSOrganic fine chemistryMIRATI THERAPEUTICS, INC.
Dec 18, 20252025/0381272TREATMENT METHODS FOR SECOND LINE THERAPY OF CD19-TARGETED CAR T CELLSPharmaceuticalsJuno Therapeutics, Inc.
Dec 11, 20252025/0376536MULTISPECIFIC ANTI-CD40 / ANTI-FAP ANTIBODIES AND USES THEREOFPharmaceuticalsBRISTOL-MYERS SQUIBB COMPANY
Dec 11, 20252025/0376483PRODRUGS OF PAN-KRAS INHIBITORSPharmaceuticalsMirati Therapeutics, Inc.
Dec 11, 20252025/0376474RET-LDD PROTEIN DEGRADERSOrganic fine chemistryBRISTOL-MYERS SQUIBB COMPANY
Dec 11, 20252025/0375451CHIRAL DIARYL MACROCYCLES AND USES THEREOFPharmaceuticalsTURNING POINT THERAPEUTICS, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 238 · Organic fine chemistry 96 · Biotechnology 55 · Medical technology 31 · Analysis of biological materials 20 · Computer technology 7.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BMY · research, not advice